Apellis Pharmaceuticals

Historical price data

Apellis Pharmaceuticals is on a mission to develop life-changing therapies by targeting C3, the central node of the complement cascade. The company has achieved a significant milestone with three regulatory approvals in four years, validating its platform and establishing commercial capabilities. Its strategy focuses on expanding the reach of its approved C3 inhibitor, pegcetacoplan, into new indications and geographies while advancing a pipeline of novel therapies for rare, retinal, and neurological diseases.

Proprietary platform focused on targeted inhibition of the C3 protein, the central node of the complement cascade, to achieve comprehensive control over this part of the immune system across all activation pathways.